• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735

    6/25/25 7:03:00 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VKTX alert in real time by email

    VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes

    SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of the VANQUISH Phase 3 clinical program for VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.  VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.

    The VANQUISH Phase 3 program includes two studies evaluating VK2735: one in adults with obesity and one in obese or overweight adults with type 2 diabetes.  Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks.  The VANQUISH-1 study will target enrollment of approximately 4500 adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. The VANQUISH-2 study will target enrollment of approximately 1100 adults with type 2 diabetes who are obese or overweight.  Participants in both trials will be randomized to one of four weekly treatment arms: VK2735 7.5 mg, VK2735 12.5 mg, VK2735 17.5 mg, and placebo.

    The primary endpoint of the trials is the percent change in body weight from baseline for participants receiving VK2735 as compared to placebo after 78 weeks of treatment.  Secondary and exploratory endpoints will evaluate a range of additional safety and efficacy measures, including the percentage of patients who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction.  Each study will include an open-label extension allowing participants the opportunity to continue receiving treatment following completion of the primary dosing period.

    "We are excited to advance VK2735 into Phase 3 clinical development, moving one step closer to potentially bringing this important therapeutic to patients with obesity," said Brian Lian, Ph.D., chief executive officer of Viking.  "Along with the successful initiation of the Phase 3 program we continue to make progress on VK2735's broader development.  This includes our plans to initiate an additional clinical study to evaluate a monthly maintenance regimen, which is expected to begin later this year.  We also continue to build on the encouraging early data reported for the oral tablet formulation of VK2735 and expect to report the results of the Phase 2 VENTURE-Oral Dosing study in the second half of this year." 

    In 2024, Viking announced positive top-line results from the Phase 2 VENTURE study of subcutaneous VK2735 in obesity.  The VENTURE trial successfully achieved its primary and all secondary endpoints, with patients receiving VK2735 demonstrating clinically meaningful reductions in body weight compared with placebo.  With respect to the primary endpoint after 13 weekly doses, patients receiving VK2735 demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7%, as well as statistically significant reductions in mean body weight relative to placebo, ranging up to 13.1%.  Differences compared to placebo were statistically significant for all doses starting at Week 1 and were maintained through the course of the study.  In addition, results from follow-up visits that occurred four and seven weeks after the last dose of VK2735 was administered showed that cohorts receiving VK2735 maintained the majority of their weight loss through the seven-week follow-up visit after administration of the final dose.

    VK2735 also demonstrated encouraging safety and tolerability in the VENTURE study, with the majority of observed adverse events (AEs) being reported as mild or moderate.  Treatment and study discontinuation rates among VK2735 cohorts were well-balanced compared with placebo.  Of gastrointestinal (GI) related AEs, 95% were reported as mild or moderate.  Across all cohorts in the VENTURE study, GI-related AEs were most prevalent during the first week of treatment, with observed rates generally declining through the remainder of the study. 

    About GLP-1 and Dual GLP-1/GIP Agonists

    Activation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both. Semaglutide is a GLP-1 receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently marketed in various dosage strengths and forms as Ozempic®, Rybelsus®, and Wegovy®. More recently, research efforts have explored the potential co-activation of the glucose-dependent insulinotropic peptide (GIP) receptor as a means of enhancing the therapeutic benefits of GLP-1 receptor activation. Tirzepatide is a dual GLP-1/GIP receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently marketed in various dosage strengths and forms as Mounjaro® and Zepbound®.

    About Viking Therapeutics, Inc.

    Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with two programs currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 2 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders.  In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD).  In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.

    For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.

    Forward-Looking Statements

    This press release contains forward-looking statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its clinical and preclinical development programs, anticipated timing for reporting clinical data and cash resources.  Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance.  These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product candidate development activities and clinical trials, including those for VK2735, VK0214, VK2809, and the company's other incretin receptor agonists; risks that prior clinical and preclinical results may not be replicated; risks regarding regulatory requirements; and other risks that are described in Viking's most recent periodic reports filed with the Securities and Exchange Commission including Viking's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings.  These forward-looking statements speak only as of the date hereof.  Viking disclaims any obligation to update these forward-looking statements except as required by law.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-announces-initiation-of-phase-3-obesity-clinical-program-with-glp-1gip-agonist-vk2735-302490496.html

    SOURCE Viking Therapeutics, Inc.

    Get the next $VKTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $VKTX

    DatePrice TargetRatingAnalyst
    4/29/2025$104.00Overweight
    Cantor Fitzgerald
    4/8/2025$30.00Neutral
    Goldman
    2/13/2025$102.00Sector Outperform
    Scotiabank
    2/7/2025$38.00Neutral
    Citigroup
    12/2/2024Overweight
    Piper Sandler
    11/22/2024$109.00Buy
    B. Riley Securities
    11/4/2024$90.00 → $102.00Buy
    H.C. Wainwright
    9/11/2024$80.00Overweight
    JP Morgan
    More analyst ratings

    $VKTX
    SEC Filings

    See more
    • SEC Form 144 filed by Viking Therapeutics Inc.

      144 - Viking Therapeutics, Inc. (0001607678) (Subject)

      7/3/25 1:07:09 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viking Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Viking Therapeutics, Inc. (0001607678) (Filer)

      5/27/25 5:20:07 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Viking Therapeutics Inc.

      SCHEDULE 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

      5/12/25 10:43:30 AM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VKTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4)

      4/A - Viking Therapeutics, Inc. (0001607678) (Issuer)

      4/8/25 7:05:30 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4)

      4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

      4/2/25 6:29:36 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VKTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735

      VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of the VANQUISH Phase 3 clinical program for VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.  VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity. The VANQUI

      6/25/25 7:03:00 AM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viking Therapeutics to Participate at Upcoming Investor Conferences

      SAN DIEGO, May 28, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences.  Details of the company's participation are as follows: William Blair 45th Annual Growth Stock ConferenceDetails: Viking management will deliver a corporate presentation, and participate in a fireside chat and 1-on-1 meetingsConference Date: June 3-5, 2025Presentation T

      5/28/25 4:05:00 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Conference call scheduled for 4:30 p.m. ET today Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully Enrolled; Data Expected 2H25Broad Manufacturing Agreement with CordenPharma to Support Future Commercialization of VK2735Strong Quarter-End Cash Position of $852 MillionSAN DIEGO, April 23, 2025 /PRNewswire/ --Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2025, and provided an update on its clinical pipeline and other corporate

      4/23/25 4:05:00 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VKTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Viking Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Viking Therapeutics with a rating of Overweight and set a new price target of $104.00

      4/29/25 8:13:00 AM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Viking Therapeutics with a new price target

      Goldman initiated coverage of Viking Therapeutics with a rating of Neutral and set a new price target of $30.00

      4/8/25 9:33:02 AM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Viking Therapeutics with a new price target

      Scotiabank initiated coverage of Viking Therapeutics with a rating of Sector Outperform and set a new price target of $102.00

      2/13/25 8:13:09 AM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VKTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Zante Greg was granted 7,667 shares and sold $118,428 worth of shares (4,266 units at $27.76), increasing direct ownership by 2% to 168,660 units (SEC Form 4)

      4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

      7/3/25 3:31:07 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Lian Brian was granted 48,333 shares and sold $747,633 worth of shares (26,889 units at $27.80), increasing direct ownership by 0.91% to 2,388,014 units (SEC Form 4)

      4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

      7/3/25 3:31:13 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Mancini Marianna sold $118,473 worth of shares (4,266 units at $27.77) and was granted 7,667 shares, increasing direct ownership by 0.91% to 377,535 units (SEC Form 4)

      4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

      7/3/25 3:30:32 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VKTX
    Financials

    Live finance-specific insights

    See more
    • Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Conference call scheduled for 4:30 p.m. ET today Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully Enrolled; Data Expected 2H25Broad Manufacturing Agreement with CordenPharma to Support Future Commercialization of VK2735Strong Quarter-End Cash Position of $852 MillionSAN DIEGO, April 23, 2025 /PRNewswire/ --Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2025, and provided an update on its clinical pipeline and other corporate

      4/23/25 4:05:00 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025

      Conference Call Scheduled for Wednesday, April 23 at 4:30 p.m. Eastern Time SAN DIEGO, April 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2025 after the market close on Wednesday, April 23, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on We

      4/16/25 4:05:00 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

      Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25Phase 2 VENTURE-Oral Dosing Trial Evaluating VK2735 in Obesity UnderwayStrong Year-End Cash Position of $903 MillionSAN DIEGO, Feb. 5, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2024, and provided an update on its clinical pipeline and other corporate developments.

      2/5/25 4:05:00 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VKTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

      SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

      11/14/24 4:30:54 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

      SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

      11/12/24 5:54:36 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

      SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

      11/4/24 1:54:45 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care